Literature DB >> 324364

Treatment of idiopathic thrombocytopenic purpura (ITP).

Y S Ahn, W J Harrington.   

Abstract

In summary, idiopathic thrombocytopenic purpura (as defined here) should be treated initially with glucocorticoids unless there is life-threatening hemorrhage (such as intracranial bleeding), in which case emergency splenectomy is indicated, since it generally gives the most prompt improvement in platelet count of all modes of the disease and to better define the cause of the thrombocytopenia. A complete, sustained remission following treatment with steroids may occasionally be obtained. In most cases the steroid response is transient, and splenectomy is the most definitive measure with respect to a lifelong cure. Complete clinical cure is obtained in 70-80% of instances following splenectomy, with a very low operative risk. The remainder either fail to respond or experience relapse. In this group of patients steroids should again be tried; if a good response is obtained, steroids should be given every second or third day to lessen long-term side effects. If these measures fail, the use of immunosuppressive agents is justified. Both vinca alkaloids and cyclophosphamide are especially useful. Vinca alkaloids act more promptly, but cyclophosphamide may have a more lasting effect. Azathioprine may also be used; however, it appears to yield a lower remission rate. Nonsteroidal immunosuppressive agents should not be used as the primary modality of therapy. And, due to their carcinogenic and teratogenic potential, they should be avoided, if possible, especially in children and in women during their childbearing years.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324364     DOI: 10.1146/annurev.me.28.020177.001503

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  11 in total

1.  Chronic idiopathic thrombocytogenic purpura.

Authors:  G F Pineo
Journal:  Can Fam Physician       Date:  1984-09       Impact factor: 3.275

2.  Perinatal management of idiopathic thrombocytopenic purpura in pregnancy: risk factors for passive immune thrombocytopenia.

Authors:  H Yamada; S Fujimoto
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

3.  [Therapy of a refractory idiopathic thrombocytopenic purpura by vinblastine-loaded thrombocytes (author's transl)].

Authors:  U Budde; R Schmidt; J Gerloff; F Etzel
Journal:  Blut       Date:  1979-02-19

4.  Treatment of thrombocytopenia with alfa interferon.

Authors:  A M Lever; M G Brook; I Yap; H C Thomas
Journal:  Br Med J (Clin Res Ed)       Date:  1987-12-12

Review 5.  Immunosuppressant therapy of idiopathic thrombocytopenic purpura.

Authors:  Y S Ahn; W J Harrington; R Mylvaganam
Journal:  Springer Semin Immunopathol       Date:  1984

Review 6.  Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura.

Authors:  D Z Edelmann; B Knobel; I Virag; D Meytes
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

7.  Immunologic studies before and after splenectomy in a patient with the Wiskott-Aldrich syndrome.

Authors:  A P Knutsen; W F Rosse; T R Kinney; R H Buckley
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

8.  Idiopathic thrombocytopenic purpura in pregnancy and neonatal period.

Authors:  G Wenske; G Gaedicke; H Heyes
Journal:  Blut       Date:  1984-06

Review 9.  Surgical treatment of immune thrombocytopenic purpura.

Authors:  P Chirletti; M Cardi; P Barillari; A Vitale; P Sammartino; A Bolognese; R Caiazzo; M Ricci; I A Muttillo; V Stipa
Journal:  World J Surg       Date:  1992 Sep-Oct       Impact factor: 3.352

10.  Serious complications following treatment of chronic idiopathic thrombocytopenic purpura.

Authors:  W Wanachiwanawin; S Visudhiphan; A Piankijagum; S Vatanavicharn
Journal:  Postgrad Med J       Date:  1988-06       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.